Hitoshi Ohno
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hitoshi Ohno has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
Takashi Uchiyama
Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin‐Kawaramachi, Sakyo‐ku, Kyoto 606–8507
8 shared publicationsChiyoko Ueda
7 shared publicationsTakashi Akasaka
First Division, Department of Internal Medicine, Faculty of Medicine, Kyoto University, 54-Shogoin-Kawaramachi, Sakyo-ku, Kyoto 606-8507, Japan
5 shared publications- Takashi Akasaka
Department of Hematology, Tenri Hospital
5 shared publications Masayuki Kurata
Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Japan
4 shared publicationsYoshitomo Maesako
4 shared publications
Latest Publications
- 1 January 2016
- Published by Tenri Foundation, Tenri Institute of Medical Research in Tenri Medical Bulletin
- Vol. 19 (1) , 24-33
MYC/BCL2/BCL6 triple-hit lymphoma that presented with a suprasellar tumor and meningeal dissemination: A case report
- 1 January 2016
- Published by Tenri Foundation, Tenri Institute of Medical Research in Tenri Medical Bulletin
- Vol. 19 (1) , 24-33
MYC/BCL2/BCL6 triple-hit lymphoma that presented with a suprasellar tumor and meningeal dissemination: A case report
- 1 January 2014
- Published by Tenri Foundation, Tenri Institute of Medical Research in Tenri Medical Bulletin
- Vol. 17 (2) , 72-80
Acute monocytic leukemia carrying t(11;17)(q23;p13)/MLL-GAS7 that developed shortly after R-CHOP chemotherapy
- 1 January 2014
- Published by Tenri Foundation, Tenri Institute of Medical Research in Tenri Medical Bulletin
- Vol. 17 (2) , 72-80
Acute monocytic leukemia carrying t(11;17)(q23;p13)/MLL-GAS7 that developed shortly after R-CHOP chemotherapy
- 1 January 2013
- Published by Tenri Foundation, Tenri Institute of Medical Research in Tenri Medical Bulletin
- Vol. 16 (2) , 133-135
Acquired hemophilia A
- 1 January 2013
- Published by Tenri Foundation, Tenri Institute of Medical Research in Tenri Medical Bulletin
- Vol. 16 (2) , 133-135
Acquired hemophilia A
- 1 January 2012
- Published by Japanese Society of Pharmaceutical Health Care and Sciences in Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
- Vol. 38 (11) , 688-693
Evaluation of the Drug Interactions between Cyclosporin A and Azole Antifungals in Hematopoietic Stem Cell Transplant Recipients
- 1 January 2012
- Published by Japanese Society of Pharmaceutical Health Care and Sciences in Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
- Vol. 38 (11) , 688-693
Evaluation of the Drug Interactions between Cyclosporin A and Azole Antifungals in Hematopoietic Stem Cell Transplant Recipients
- Open Access
- 1 September 2003
- Published by Wiley in Cancer Science
- Vol. 94 (9) , 774-781
Comparison of gene expression profiles of lymphoma cell lines from transformed follicular lymphoma, Burkitt's lymphoma and de novo diffuse large B‐cell lymphoma
To determine the specific gene expression in B‐cell lymphoma subtypes, we compared expression profiles of cell lines from transformed follicular lymphoma (tFL), Epstein‐Barr virus‐negative (EBV(‐)) Burkitt's lymphoma (BL) and EBV(+)BL. Complementary DNAs were synthesized from these cell lines and hybridized with the Atlas Human 1.2 Array membrane. Hierarchical clustering analysis based upon the levels of 43 genes highlighted characteristic expression patterns of the 3 lymphoma subtypes. Genes expressed at higher levels in tFL than EBV(‐)BL and EBV(+)BL included calcium/calmodulin‐dependent protein kinase I (CAMK1) and mitogen‐activated protein kinase 10 (MAPK10). EBV(‐)BL was characterized by high‐level expression of amyloid β precursor protein (APP), heat shock 27 kD protein 1 (HSPB1) and mothers against decapentaplegic homolog 1 (MADH1). Gardner‐Rasheed feline sarcoma viral oncogene homolog (FGR) was the most significant gene to delineate EBV(+)BL. A subtype prediction algorithm using 34 genes correctly classified 22 (92%) of 24 lymphomas into FL/tFL, EBV(‐)BL or EBV(+)BL. By comparison with normal reference B‐cell materials, the expression patterns of the selected genes were characteristic of lymphomas. We extended the clustering analysis to cell lines from de novo diffuse large B‐cell lymphoma (DLBCL). The DLBCL cell lines were either separated from the former 3 lymphoma subtypes or segregated with EBV(+)BL, possibly reflecting variable genetic abnormalities. The associations of CAMK1 with tFL, APP and MADH1 with EBV(‐)BL, FGR with EBV(+)BL, and BCL2 with tFL and DLBCL were confirmed by real‐time quantitative reverse transcriptase‐medizted polymerase chain reaction assays. This study has provided new molecular markers, expressions of which are closely associated with B‐cell lymphoma subtypes.
- 1 September 2003
- Published by Wiley in Cancer Science
- Vol. 94 (9) , 774-781
Open AccessComparison of gene expression profiles of lymphoma cell lines from transformed follicular lymphoma, Burkitt's lymphoma and de novo diffuse large B‐cell lymphoma
To determine the specific gene expression in B‐cell lymphoma subtypes, we compared expression profiles of cell lines from transformed follicular lymphoma (tFL), Epstein‐Barr virus‐negative (EBV(‐)) Burkitt's lymphoma (BL) and EBV(+)BL. Complementary DNAs were synthesized from these cell lines and hybridized with the Atlas Human 1.2 Array membrane. Hierarchical clustering analysis based upon the levels of 43 genes highlighted characteristic expression patterns of the 3 lymphoma subtypes. Genes expressed at higher levels in tFL than EBV(‐)BL and EBV(+)BL included calcium/calmodulin‐dependent protein kinase I (CAMK1) and mitogen‐activated protein kinase 10 (MAPK10). EBV(‐)BL was characterized by high‐level expression of amyloid β precursor protein (APP), heat shock 27 kD protein 1 (HSPB1) and mothers against decapentaplegic homolog 1 (MADH1). Gardner‐Rasheed feline sarcoma viral oncogene homolog (FGR) was the most significant gene to delineate EBV(+)BL. A subtype prediction algorithm using 34 genes correctly classified 22 (92%) of 24 lymphomas into FL/tFL, EBV(‐)BL or EBV(+)BL. By comparison with normal reference B‐cell materials, the expression patterns of the selected genes were characteristic of lymphomas. We extended the clustering analysis to cell lines from de novo diffuse large B‐cell lymphoma (DLBCL). The DLBCL cell lines were either separated from the former 3 lymphoma subtypes or segregated with EBV(+)BL, possibly reflecting variable genetic abnormalities. The associations of CAMK1 with tFL, APP and MADH1 with EBV(‐)BL, FGR with EBV(+)BL, and BCL2 with tFL and DLBCL were confirmed by real‐time quantitative reverse transcriptase‐medizted polymerase chain reaction assays. This study has provided new molecular markers, expressions of which are closely associated with B‐cell lymphoma subtypes.
- 1 November 2002
- Vol. 62 (21) , 6224-30
Characterization of t(3;6)(q27;p21) breakpoints in B-cell non-Hodgkin's lymphoma and construction of the histone H4/BCL6 fusion gene, leading to altered expression of Bcl-6.
A recurrent translocation, t(3;6)(q27;p21), in non-Hodgkin's lymphoma results in fusion of BCL6 with a particular histone H4 gene on 6p21. We cloned five H4/BCL6 junctions from both der(3) and der(6) chromosomes. The breakpoints on H4 were distributed within the single exon or close to the terminal palindrome, and those on BCL6 were localized within or close to the translocation hypercluster. Deletions or duplications of variable numbers of nucleotides were identified at the junctions. A total of eight single nucleotide alterations were introduced into the translocation/mutation cluster of BCL6, whereas four single nucleotide substitutions were identified within a 360-bp region of H4. Thus, the somatic hypermutation mechanism is likely to target H4, resulting in a predisposition to the development of translocation with BCL6. Lymphoma cells carrying H4/BCL6 produced fusion transcripts containing both H4 and BCL6 messages; however, the cells expressed only moderate levels of BCL6 mRNA. We constructed expression plasmids that mimicked the H4/BCL6 fusion gene and transiently introduced them into COS-7 cells. H4/BCL6-transfected cells expressed markedly higher levels of Bcl-6 protein than cells transfected with a plasmid carrying BCL6 driven by its normal promoter and displayed bright nuclear staining with a characteristic punctate pattern with an anti-Bcl-6 antibody. Deletion analyses revealed that the high-level Bcl-6 expression was promoted by the H4 regulatory sequences. The levels of expression of activating transcription factor 3, prefoldin 4, and retinoblastoma-binding protein 7 significantly increased in accordance with that of BCL6, suggesting that Bcl-6 may act as a transcriptional activator. Our study suggested that t(3;6)(q27;p21) leads to BCL6 overexpression; however, the high-level BCL6 expression may not be required to maintain the malignant phenotype of lymphoma cells.
- 1 November 2002
- Vol. 62 (21) , 6224-30
Characterization of t(3;6)(q27;p21) breakpoints in B-cell non-Hodgkin's lymphoma and construction of the histone H4/BCL6 fusion gene, leading to altered expression of Bcl-6.
A recurrent translocation, t(3;6)(q27;p21), in non-Hodgkin's lymphoma results in fusion of BCL6 with a particular histone H4 gene on 6p21. We cloned five H4/BCL6 junctions from both der(3) and der(6) chromosomes. The breakpoints on H4 were distributed within the single exon or close to the terminal palindrome, and those on BCL6 were localized within or close to the translocation hypercluster. Deletions or duplications of variable numbers of nucleotides were identified at the junctions. A total of eight single nucleotide alterations were introduced into the translocation/mutation cluster of BCL6, whereas four single nucleotide substitutions were identified within a 360-bp region of H4. Thus, the somatic hypermutation mechanism is likely to target H4, resulting in a predisposition to the development of translocation with BCL6. Lymphoma cells carrying H4/BCL6 produced fusion transcripts containing both H4 and BCL6 messages; however, the cells expressed only moderate levels of BCL6 mRNA. We constructed expression plasmids that mimicked the H4/BCL6 fusion gene and transiently introduced them into COS-7 cells. H4/BCL6-transfected cells expressed markedly higher levels of Bcl-6 protein than cells transfected with a plasmid carrying BCL6 driven by its normal promoter and displayed bright nuclear staining with a characteristic punctate pattern with an anti-Bcl-6 antibody. Deletion analyses revealed that the high-level Bcl-6 expression was promoted by the H4 regulatory sequences. The levels of expression of activating transcription factor 3, prefoldin 4, and retinoblastoma-binding protein 7 significantly increased in accordance with that of BCL6, suggesting that Bcl-6 may act as a transcriptional activator. Our study suggested that t(3;6)(q27;p21) leads to BCL6 overexpression; however, the high-level BCL6 expression may not be required to maintain the malignant phenotype of lymphoma cells.
- Open Access
- 1 April 2002
- Published by American Society of Hematology in Blood
- Vol. 99 (7) , 2624-2625
Immunoglobulin (Ig)/BCL6 versus non-Ig/BCL6 gene fusion in diffuse large B-cell lymphoma corresponds to a high- versus low-level expression of BCL6mRNA
- 1 April 2002
- Published by American Society of Hematology in Blood
- Vol. 99 (7) , 2624-2625
Open AccessImmunoglobulin (Ig)/BCL6 versus non-Ig/BCL6 gene fusion in diffuse large B-cell lymphoma corresponds to a high- versus low-level expression of BCL6mRNA
- 1 March 2002
- Vol. 43 (3) , 170-5
[Significance of soluble interleukin-2 receptor alpha chain in the management of patients with malignant lymphoma: a multi-center study].
A multi-center series of 117 patients with malignant lymphoma were analyzed to evaluate the clinical significance of soluble interleukin-2 receptor alpha chain (sIL-2R alpha). The initial levels of sIL-2R alpha ranged from 277 U/ml to 22,800 U/ml with a mean level of 3,451 +/- 4,268 U/ml and a median level of 1,600 U/ml. The sIL-2R alpha levels of the diffuse lymphoma/intermediate-grade subtypes defined by the LSG classification/Working Formulation were higher than those of the follicular lymphoma/low-grade subtypes. There was a tendency for B-cell lymphomas to show higher sIL-2R alpha levels than T-cell lymphomas. The sIL-2R alpha level was correlated with the Ann Arbor clinical stage (I, II versus III, IV), presence or absence of B symptoms, and performance status (0, 1 versus 2, 3, 4) of the patients. The sIL-2R alpha levels were in good accordance with the four risk groups defined by the International Prognostic Indices. Of 21 patients whose tumor burden was serially measured, the coefficients of correlation between sIL-2R alpha and tumor mass were > 0.6 in 18 cases. Sixty-two patients achieved complete remission (CR) during the study; the initial and minimum sIL-2R alpha levels were lower than those of the non-CR patients. This study confirmed that sIL-2R alpha is a convenient and useful marker in the management of malignant lymphoma.
- 1 March 2002
- Vol. 43 (3) , 170-5
[Significance of soluble interleukin-2 receptor alpha chain in the management of patients with malignant lymphoma: a multi-center study].
A multi-center series of 117 patients with malignant lymphoma were analyzed to evaluate the clinical significance of soluble interleukin-2 receptor alpha chain (sIL-2R alpha). The initial levels of sIL-2R alpha ranged from 277 U/ml to 22,800 U/ml with a mean level of 3,451 +/- 4,268 U/ml and a median level of 1,600 U/ml. The sIL-2R alpha levels of the diffuse lymphoma/intermediate-grade subtypes defined by the LSG classification/Working Formulation were higher than those of the follicular lymphoma/low-grade subtypes. There was a tendency for B-cell lymphomas to show higher sIL-2R alpha levels than T-cell lymphomas. The sIL-2R alpha level was correlated with the Ann Arbor clinical stage (I, II versus III, IV), presence or absence of B symptoms, and performance status (0, 1 versus 2, 3, 4) of the patients. The sIL-2R alpha levels were in good accordance with the four risk groups defined by the International Prognostic Indices. Of 21 patients whose tumor burden was serially measured, the coefficients of correlation between sIL-2R alpha and tumor mass were > 0.6 in 18 cases. Sixty-two patients achieved complete remission (CR) during the study; the initial and minimum sIL-2R alpha levels were lower than those of the non-CR patients. This study confirmed that sIL-2R alpha is a convenient and useful marker in the management of malignant lymphoma.
- 1 October 2001
- Published by Elsevier in Cancer Genetics and Cytogenetics
- Vol. 130 (1) , 42-50
Establishment and characterization of a new human myeloma cell line, KYδ-1, producing the δ/κ type immunoglobulin
- 1 October 2001
- Published by Elsevier in Cancer Genetics and Cytogenetics
- Vol. 130 (1) , 42-50
Establishment and characterization of a new human myeloma cell line, KYδ-1, producing the δ/κ type immunoglobulin
- 1 September 2001
- Published by Wiley in Japanese Journal of Cancer Research
- Vol. 92 (9) , 933-940
Heterogeneous Breakpoints on the Immunoglobulin Genes Are Involved in Fusion with the 5′ Region of BCL2 in B‐Cell Tumors
The 5′flanking region of the BCL2 gene (5′‐BCL2) is a breakpoint cluster of rearrangements with immunoglobulin genes (IGs). In contrast to t(14;18)(q32;q21) affecting the 3’region of BCL2, 5′‐BCL2 can fuse to not only the heavy chain gene (IGH), but also two light chain gene (IGL) loci. We report here cloning and sequencing of a total of eleven 5′‐BCL2/IGs junctional areas of B‐cell tumors, which were amplified by long‐distance polymerase chain reaction‐based assays. The breakpoints on 5′‐BCL2 were distributed from 378 to 2312 bp upstream of the translational initiation site and, reflecting the alteration of regulatory sequences of BCL2, 5′‐BCL2/IGs‐positive cells showed markedly higher levels of BCL2 expression than those of t(14;18)‐positive cells. In contrast, the breakpoints on the IGs were variable. Two 5′‐BCL2/IGH and two 5′‐BCL2/IGLK junctions occurred 5’of the joining (J) segments, suggesting operation of an erroneous variable (V)/diversity (D)/J and V/J rearrangement mechanism. However, two other 5′‐BCL2/IGH junctions affected switch regions, and the K‐deleting element, which is located 24 kb downstream of the constant region of IGLK, followed the 5′‐BCL2 in another case. One 5′‐BCL2/IGLK and two 5′‐BCL2/IGLλ junctions involved intronic regions where the normal recombination process does not occur. In the remaining one case, the 5′‐BCL2 fused 3’of a Vλ, gene that was upstream of another Vλ/Jλ complex carrying a non‐producing configuration, indicating that the receptor editing mechanism was likely involved in this rearrangement. Our study revealed heterogeneous anatomy of the 5′‐BCL2/IGs fusion gene leading to transcriptional activation of BCL2, and suggested that the mechanisms underlying the formation of this particular oncogene/IGs recombination are not identical to those of t(14;18).
- 1 September 2001
- Published by Wiley in Japanese Journal of Cancer Research
- Vol. 92 (9) , 933-940
Heterogeneous Breakpoints on the Immunoglobulin Genes Are Involved in Fusion with the 5′ Region of BCL2 in B‐Cell Tumors
The 5′flanking region of the BCL2 gene (5′‐BCL2) is a breakpoint cluster of rearrangements with immunoglobulin genes (IGs). In contrast to t(14;18)(q32;q21) affecting the 3’region of BCL2, 5′‐BCL2 can fuse to not only the heavy chain gene (IGH), but also two light chain gene (IGL) loci. We report here cloning and sequencing of a total of eleven 5′‐BCL2/IGs junctional areas of B‐cell tumors, which were amplified by long‐distance polymerase chain reaction‐based assays. The breakpoints on 5′‐BCL2 were distributed from 378 to 2312 bp upstream of the translational initiation site and, reflecting the alteration of regulatory sequences of BCL2, 5′‐BCL2/IGs‐positive cells showed markedly higher levels of BCL2 expression than those of t(14;18)‐positive cells. In contrast, the breakpoints on the IGs were variable. Two 5′‐BCL2/IGH and two 5′‐BCL2/IGLK junctions occurred 5’of the joining (J) segments, suggesting operation of an erroneous variable (V)/diversity (D)/J and V/J rearrangement mechanism. However, two other 5′‐BCL2/IGH junctions affected switch regions, and the K‐deleting element, which is located 24 kb downstream of the constant region of IGLK, followed the 5′‐BCL2 in another case. One 5′‐BCL2/IGLK and two 5′‐BCL2/IGLλ junctions involved intronic regions where the normal recombination process does not occur. In the remaining one case, the 5′‐BCL2 fused 3’of a Vλ, gene that was upstream of another Vλ/Jλ complex carrying a non‐producing configuration, indicating that the receptor editing mechanism was likely involved in this rearrangement. Our study revealed heterogeneous anatomy of the 5′‐BCL2/IGs fusion gene leading to transcriptional activation of BCL2, and suggested that the mechanisms underlying the formation of this particular oncogene/IGs recombination are not identical to those of t(14;18).